OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Update on Use of Immunotherapy in Hematologic Malignancies

home / peer-exchange / heme-update-immunotherapy
Immunotherapy in Hematologic Malignancies

EP. 1: Immunotherapy in Hematologic Malignancies

June 24th 2015
Responses With Immunotherapy Versus Chemotherapy

EP. 2: Responses With Immunotherapy Versus Chemotherapy

June 24th 2015
Immunotherapy-Related Adverse Events

EP. 3: Immunotherapy-Related Adverse Events

June 24th 2015
Rituximab, Obinutuzumab, and Ofatumumab in CLL

EP. 4: Rituximab, Obinutuzumab, and Ofatumumab in CLL

June 24th 2015
Blinatumomab in Philadelphia Chromosome-Negative ALL

EP. 5: Blinatumomab in Philadelphia Chromosome-Negative ALL

June 24th 2015
Measuring Response to Novel Therapies in ALL

EP. 6: Measuring Response to Novel Therapies in ALL

June 24th 2015
Elotuzumab in Relapsed/Refractory Multiple Myeloma

EP. 7: Elotuzumab in Relapsed/Refractory Multiple Myeloma

June 24th 2015
Daratumumab, Vaccines in Multiple Myeloma

EP. 8: Daratumumab, Vaccines in Multiple Myeloma

June 24th 2015
Treatment Advancements in Lymphoma

EP. 9: Treatment Advancements in Lymphoma

June 24th 2015
PD-1 Inhibition in Hodgkin's Lymphoma

EP. 10: PD-1 Inhibition in Hodgkin's Lymphoma

June 24th 2015
Future Immunotherapies for Hematologic Malignancies

EP. 11: Future Immunotherapies for Hematologic Malignancies

June 24th 2015

Latest Conference Coverage

Ribociclib/Endocrine Therapy Yields Similar pCRs Compared With Chemotherapy in HR+ Early Breast Cancer

Emiltatug Ledadotin Shows Early Clinical Activity and Safety in Advanced/Metastatic TNBC

Puxitatug Samrotecan Yields Responses With Manageable Safety in Pretreated HR+/HER2– Advanced Breast Cancer

Adjuvant Pertuzumab Plus Trastuzumab and Chemotherapy Leads to OS Benefit in Early-Stage HER2+ Breast Cancer

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact